Treatment of primary cutaneous CD30+ anaplastic large-cell lymphoma with radiation therapy.
OBJECTIVE
Primary cutaneous CD30+ anaplastic large-cell lymphoma (CALCL) is a relatively rare and indolent variant of cutaneous T-cell lymphoma (CTCL). This report examines the response of localized disease to radiation alone.


METHODS
The Yale Cancer Center records were examined, and all patients with CTCL from January 1, 2001, to September 1, 2006, evaluated in the Department of Therapeutic Radiology were identified. Only those patients with localized or single CALCL lesions, no clinical evidence or history of lymphomatoid papulosis, no history of other CTCLs, no history of other skin disorders, lack of lymph node involvement, unambiguous pathology reports, and treatment with radiation alone were included.


RESULTS
Eight patients were identified. Median age was 67 years, and gender was split evenly. Patients received radiation ranging from 34 to 44 Gy in 2-Gy fractions. Most patients (5 of 8) received 40 Gy, using 6 to 9 MeV electrons with 0.5 to 2 cm of bolus. All patients had a complete response. All patients were without evidence of disease at the most recent follow-up (median follow-up, 12 months). Radiation therapy was well tolerated, and the only recorded toxicity was Grade I to II dermatitis.


CONCLUSIONS
Radiation therapy alone for localized CALCL is very well tolerated and clinical response is excellent. A dose of 40 Gy in 2-Gy fractions seems to be well tolerated and effective in inducing a complete response. Lower doses may be effective in achieving the same result, but data are not available. Longer follow-up is necessary before conclusions regarding durable disease-free survival can be made.
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06520-8040, USA.
James B
JB
Yu
Jennifer M
JM
McNiff
Molly W
MW
Lund
Lynn D
LD
Wilson
D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D017730:Ki-1 Antigen; D054446:Lymphoma, Primary Cutaneous Anaplastic Large Cell / Q000276:immunology / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000276:immunology / Q000473:pathology / Q000532:radiotherapy*
D017730:Ki-1 Antigen